http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-19990065213-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-16 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 1998-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1999-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-19990065213-A |
| titleOfInvention | Fusion protein expression vector activated by extracellular antibody to induce cell death |
| abstract | The present invention provides an extracellular domain and genetically induced apoptosis (apoptosis, programmed cell) of CD8, a surface protein that is important for inducing an immune response in human T cells on the surface of human CD4 +, CD8- T cells, Jurkat T cells. The cytoplasmic region of Fas, a surface protein important for causing death, provides a novel transformed cell line that stably expresses a fused protein. The cell line of the present invention produced a DNA structure in which the extracellular and transmembrane regions of CD8, the surface protein of T lymphocytes, were fused to the cytoplasmic region of Fas, thereby expressing human Jurkat without CD8 expression. T cells were constructed by injecting them by electroporation. This cell line enables immunoprecipitation of Fas proteins using OKT antibodies, which was not possible with conventional methods, and thus further studies on the discovery and interaction of new cell-induced death-related signaling agents that bind to the cytoplasmic part of Fas. It has the advantage of being easy to do. The cell line will also present a new phase in the development of next-generation anticancer and autoimmune therapeutics as a useful cell line to discover new enzymes and proteins involved in the genetic induction of cells. |
| priorityDate | 1998-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.